KR20090040759A - Composition for anticoagulation comprising cattail pollen extracts - Google Patents

Composition for anticoagulation comprising cattail pollen extracts Download PDF

Info

Publication number
KR20090040759A
KR20090040759A KR1020070106254A KR20070106254A KR20090040759A KR 20090040759 A KR20090040759 A KR 20090040759A KR 1020070106254 A KR1020070106254 A KR 1020070106254A KR 20070106254 A KR20070106254 A KR 20070106254A KR 20090040759 A KR20090040759 A KR 20090040759A
Authority
KR
South Korea
Prior art keywords
extract
composition
cattail pollen
precipitate
active ingredient
Prior art date
Application number
KR1020070106254A
Other languages
Korean (ko)
Other versions
KR100913370B1 (en
Inventor
구자형
윤철
박혜민
오만진
Original Assignee
충남대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 충남대학교산학협력단 filed Critical 충남대학교산학협력단
Priority to KR1020070106254A priority Critical patent/KR100913370B1/en
Publication of KR20090040759A publication Critical patent/KR20090040759A/en
Application granted granted Critical
Publication of KR100913370B1 publication Critical patent/KR100913370B1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

An antithrombotic composition comprising cattail pollen extracts having excellent thrombolytic activity is provided to prevent and treat adult diseases such as hypertension and paralysis. An antithrombotic composition comprises cattail pollen extracts. The cattail pollen extract is obtained by adding water of 5-20 times to cattail pollen and freeze-drying it. The cattail pollen extract forms precipitate by additionally injecting acetone of 4~6 times (v/v), and freeze-drying it after filtering the precipitate.

Description

부들 화분 추출물을 함유하는 항혈전 조성물{Composition for anticoagulation comprising cattail pollen extracts}Composition for anticoagulation comprising cattail pollen extracts

본 발명은 혈전용해능이 우수한 항혈전 조성물에 관한 것으로, 보다 상세하게는 혈전용해능이 우수하면서도 독성이 없어 안전하게 이용할 수 있는 부들화분의 물 추출물을 유효성분으로 함유하는 항혈전 조성물에 관한 것이다.The present invention relates to an antithrombotic composition having excellent thrombolytic ability, and more particularly, to an antithrombotic composition containing a water extract of a bud pollen as an active ingredient having excellent thrombolytic ability and no toxicity.

부들은 부들과의 다년초 외떡잎식물로서, 연못이나 하천, 강, 늪지 등에서 볼 수 있는데, 근경이 가로로 뻗고 굵으며, 줄기는 원주형으로 곧게 서고, 잎은 선형으로서 좁고 길며 녹색이다. 부들의 꽃가루는 수촉 혹은 포황(蒲黃)이라 하며 맛이 달고 독성이 없어 한방에서 지혈제, 자궁출혈, 토혈, 출혈성하리, 탈항, 소염성 이뇨약, 치질, 대하증, 월경불순, 방광염 등의 약재로 사용하여 왔다. 포황에는 lysine을 포함한 유리아미노산의 함량이 높고 미량원소, 비타민이 다량 함유되어 있으며 amylase, invertase등과 같은 여러 종류의 효소활성이 높다. 부들의 싹(蒲黃苗)인 향포(香蒲)는 입 안이 헤어지면서(爛) 냄새나는 것을 치료하고 이를 든든하게 하며 눈과 귀를 밝게 한다. Buds are perennial monocotyledonous plants, and can be found in ponds, streams, rivers, and swamps. Roots extend horizontally and thickly, and stems are straight in a columnar shape. Leaves are narrow, long, and green. The pollen of the buds is called cactus or huang (하며 黃), and it is sweet and not toxic, so it is a medicine such as hemostatic agent, uterine bleeding, hemorrhage, hemorrhagic hari, desalination, anti-inflammatory diuretic medicine, hemorrhoids, hypothalamus, dysmenorrhea, cystitis Has been used. The turmeric contains high amounts of free amino acids, including lysine, high amounts of trace elements and vitamins, and high enzyme activity such as amylase and invertase. Hyangpo (香蒲), the bud of the buds, breaks down the mouth and treats the smell and makes it strong and brightens the eyes and ears.

일반적으로 화분은 단단한 세포막을 가지고 있어 생물학적 분해 작용이 안정하여 수명이 길어 수 백 년이 지나더라도 화분으로서 생명을 보유하고 있는 것도 있으며 섭취한다 하더라도 인체 내에서 흡수율이 떨어져 유효성분이 제대로 이용되지 못할 때도 있다. 이러한 이유로, 각종 영양성분이 풍부한 화분을 약재나 건강기능성 식품으로 유효하게 이용하기 위한 연구가 필요하게 되었다. In general, pollen has a solid cell membrane, so its biodegradation is stable, and its life span is long, and even after several hundred years, some pollen retains its life, and even if it is ingested, its effective absorption is not properly used. . For this reason, research has been needed to effectively use potted plants rich in various nutrients as medicines or health functional foods.

인간의 삶에 있어서 암과 심혈관 질환 등 각종 질병은 수명을 단축하는 원인이 되고 있다. 뇌출혈, 심장마비, 뇌 혈전증 등과 같은 심혈관 질환은 여러 가지 원인에 의하여 생성된 혈전이 미세혈관에 축척되어 혈액순환의 장애를 일으키고 각 조직으로 영양분과 산소공급이 원활하지 못하게 되어 혈압이 높아지거나 혈관을 막음으로 일어나게 된다. 근래 심혈관계 질환으로 인한 사망률이 높아지면서 심혈관계 질환의 주원인인 혈전을 용해하는 혈전용해제에 대한 관심이 증가하고 있다. Various diseases such as cancer and cardiovascular diseases in human life are causing shortening of lifespan. Cardiovascular diseases, such as cerebral hemorrhage, heart attack, and cerebral thrombosis, are caused by blood clots produced by various causes that accumulate in the microvascular vessels, causing blood circulation problems. It happens by blocking. Recently, as the mortality rate from cardiovascular diseases increases, there is increasing interest in thrombolytics that dissolve blood clots, the main cause of cardiovascular diseases.

혈전은 상처가 복구될 때 생체내의 복잡한 생성기작에 의하여 활성화된 트롬빈(thrombin)이 혈액중에 존재하는 피브리노겐(fibrinogen)을 피브린(fibrin)으로 변화시켜 불용성의 중합체를 형성하면서 생성된다. fibrin 단량체는 수소결합에 의하여 결집되어 soft clot를 형성하고 이 clot는 여러 요인에 의하여 hard clot로 전환되어 혈전을 생성하게 된다. A thrombus is created when thrombin, activated by a complex production mechanism in vivo when a wound is repaired, converts fibrinogen present in the blood into fibrin to form an insoluble polymer. Fibrin monomers are aggregated by hydrogen bonds to form soft clots, which are converted to hard clots by a number of factors to generate thrombi.

혈전의 생성을 억제하는 항혈전제는 혈전용해제, 항혈전 활성 촉진물질, 혈액응고 저해제로 분류되며, 혈전 생성 억제물질로는 asprin을, 효소제로는 urokinase, streptokinase 등을 예로 들 수 있다. 혈전용해에 사용되고 있는 효소제는 혈전에 대한 선택성이 적어 전신 출혈이 발생할 가능성이 있으며, 가격이 비싸고 경구투여가 불가능하거나 반감기가 짧은 단점이 있는 것으로 알려져 있다. 또한, 장기 투여에 의한 부작용이나 독성이 보고되어 있는 것도 있다. Antithrombotic drugs that inhibit the formation of blood clots are classified into thrombolytic agents, antithrombotic activity promoting agents, and blood coagulation inhibitors. Examples of antithrombogenic agents include asprin and urokinase and streptokinase as enzymes. Enzymes used for thrombolysis are known to have a low selectivity to thrombosis, which may cause systemic bleeding, and are expensive, incapable of oral administration, or have short half-lives. There are also reports of side effects and toxicity from long term administration.

최근에는 상기와 같은 문제점을 해결하기 위하여 혈전을 용해하는 효능을 갖는 발효식품인 청국장, 납두(Natto), 버섯, 은행, 지렁이 등에 대한 연구가 진행되어 보고된 바 있으나, 화분에는 혈전용해능이 있다는 특허나 연구보고는 존재하지 않았다.Recently, in order to solve the above problems, studies on fermented foods such as Cheonggukjang, Natto, mushrooms, ginkgo, and earthworms have been reported. My research report did not exist.

본 발명은 상기와 같은 종래기술의 문제점을 해결하기 위한 것으로, 혈전용해효과가 우수하면서도 부작용이 없어 혈전에 의해 발생되는 고혈압, 중풍과 같은 성인병의 예방이나 치료에 사용할 수 있는 항혈전용 조성물을 제공하고자 하는 것을 목적으로 한다.The present invention is to solve the problems of the prior art as described above, to provide an anti-thrombotic composition that can be used for the prevention or treatment of adult diseases such as hypertension and stroke caused by a blood clot with excellent thrombolytic effect but no side effects. It aims to do it.

전술한 목적을 달성하기 위한 본 발명은 부들화분 추출물을 유효성분으로 하는 항혈전용 조성물에 관한 것이다.The present invention for achieving the above object relates to an anti-thrombotic composition using as an active ingredient budulhwa extract.

상기 항혈전용 조성물은 부들화분에 5~20배(v/g)의 물을 가하여 추출하는 것 에 의해 제조될 수 있다. The anti-thrombotic composition may be prepared by adding 5 to 20 times (v / g) water to the puddle flower.

상기 물의 양이 너무 적은 경우에는 추출이 효과적이지 못하며, 양이 너무 많은 경우에는 유효성분의 농도가 너무 묽어져 효율이 저하되는 것은 당연하다. 상기 추출은 10~50℃에서 이루어지는 것이 바람직하다. 추출온도가 너무 낮으면 추출이 효율적이지 못하며, 추출 온도가 50℃이상일 경우에는 유효성분이 변성될 우려가 있다.If the amount of the water is too small, the extraction is not effective, if the amount is too large it is natural that the concentration of the active ingredient is too thin to decrease the efficiency. It is preferable that the said extraction is made at 10-50 degreeC. If the extraction temperature is too low, the extraction is not efficient, if the extraction temperature is 50 ℃ or more there is a fear that the active ingredient is denatured.

상기 항혈전용 조성물은 수용액 자체로서 음용 시에 사용될 수도 있으나, 적용범위를 확장하고 사용을 보다 간편하게 하기 위해서는 분말과 같은 고체상태인 것이 보다 바람직하다. 따라서, 상기 추출액을 동결건조하는 공정을 추가로 진행하여 항혈전용 조성물을 제조할 수도 있다.The anti-thrombotic composition may be used at the time of drinking as the aqueous solution itself, but in order to expand the scope of application and to simplify the use, it is more preferable that the solid state such as powder. Therefore, by further proceeding the process of lyophilizing the extract may be prepared an anti-blood composition.

또는 상기 추출액에 (A) 추출액의 4~6배(v/v)의 아세톤을 투입하여 침전물을 형성하는 단계; 및 (B) 침전물을 여과한 후 동결건조하는 공정을 추가로 진행하는 것에 의해 항혈전용 조성물을 제조할 수도 있다. 이는 추출액 전체를 동결건조하는데 걸리는 시간을 대폭으로 줄일 수 있어 제조비용을 단축시킬 수 있을 뿐 아니라, 보다 효율적으로 대량 생산에 적용할 수 있다. 상기 혈전용해능을 갖는 유효성분은 효소로 추정되며 따라서 아세톤 침전물에는 당연히 혈전용해능이 존재할 것이다. Or (A) adding 4 to 6 times (v / v) acetone to the extract to form a precipitate; And (B) further filtering the precipitate and then lyophilizing to prepare an anti-thrombotic composition. This can drastically reduce the time it takes to lyophilize the entire extract, which can shorten the manufacturing cost and can be applied to mass production more efficiently. The active ingredient having the thrombolytic ability is assumed to be an enzyme, and therefore, the acetone precipitate will naturally have a thrombolytic ability.

전술한 방법들에 의해 제조된 부들화분의 추출물은 혈전용해능을 측정하였을 때 혈전을 녹이는 성분이 존재하는 것을 확인할 수 있었다. 또한, 종래 혈전용해능이 우수한 것으로 알려진 청국장 및 은행잎의 물 추출물과 비교하였을 때, 보다 우수한 혈전용해 효과를 나타내어 혈전용해제로서의 이용가능성이 높음을 확인할 수 있었다(도 1). 따라서, 본 발명의 항혈전용 조성물을 유효성분으로 함유하는 약제 또는 건강식품에 이용될 수 있다. The extract of the bud pollen prepared by the above-described method was able to confirm that there is a component that dissolves the thrombus when the thrombolytic ability is measured. In addition, when compared with the water extracts of Cheonggukjang and ginkgo biloba known to be excellent in conventional thrombolytic ability, it showed a more excellent thrombolytic effect, it was confirmed that the high availability as a thrombolytic agent (Fig. 1). Therefore, it can be used in pharmaceuticals or health foods containing the anti-thrombotic composition of the present invention as an active ingredient.

본 발명에 의한 부들화분의 추출물은 치료용 약제 및 식품으로 이용되기 위해서는 약제학적 및 식품학적 분야에서 공지의 방법에 의하여 제조될 수 있으며, 그 자체 또는 약학적 또는 식품학적으로 허용되는 담체(carrier), 부형제(forming agent), 희석제 등과 혼합하여 분말, 과립, 정제, 캡슐제 또는 주사제 등의 제형으로 제조되어 사용될 수 있다. 또한, 이들을 경구 또는 비경구로 투여용 제제와 같은 단위투여형 또는 수회투여형 제제로 제형화하여 항혈전 효과를 갖는 치료 및 예방제로 사용할 수 있다.The extract of the bud pollen according to the present invention can be prepared by a known method in the pharmaceutical and food science fields to be used as a therapeutic drug and food, and by itself or a pharmaceutically or food-acceptable carrier (carrier) It may be mixed and used in the formulation of powders, granules, tablets, capsules or injections by mixing with a forming agent, diluent and the like. In addition, they can be formulated into unit dosage forms or multiple dose formulations, such as oral or parenteral formulations, to be used as therapeutic and prophylactic agents having antithrombotic effects.

본 발명에 따른 유효성분의 투여량은 체내에서 활성성분의 흡수도, 활성화율 및 배설속도, 환자의 연령, 성별 및 상태, 치료할 질병의 중증정도 등에 따라 적절히 선택될 수 있다.The dosage of the active ingredient according to the present invention may be appropriately selected depending on the absorption rate, activation rate and excretion rate of the active ingredient in the body, the age, sex and condition of the patient, the severity of the disease to be treated.

이상과 같이 본 발명에 의하면 오랫동안 한방에서 사용되며 독성이 없는 것으로 입증된 부들화분의 추출물을 유효성분으로 하면서도, 기존의 항혈전 효과가 입증된 청국장이나 은행잎 추출물에 비해 혈전용해효능이 우수하여 고혈압, 중풍과 같은 성인병의 예방이나 치료에 안전하게 사용할 수 있다.As described above, according to the present invention, while using the extract of Budhwahwa, which has been used in herbal medicine for a long time and proved to be non-toxic, as an active ingredient, the antithrombotic effect has been shown to be excellent in thrombolytic activity as compared to Cheonggukjang or Ginkgo biloba extract. It can be safely used to prevent or treat adult diseases such as stroke.

이하 실시예를 통하여 본 발명을 상세하게 설명한다. 그러나, 이들 실시예는 예시적인 목적일 뿐 본 발명이 이에 한정되는 것은 아니다.The present invention will be described in detail through the following examples. However, these examples are for illustrative purposes only and the present invention is not limited thereto.

실시예Example

실시예Example 1 : 부들화분 물 추출물 1: bud pollen water extract

부들화분 1g에 물 10ml를 가하고 상온 또는 45℃에서 4시간 동안 물에 침지하였다. 4시간 후 침전으로 남아있는 부들화분을 원심분리 또는 여과에 의해 제거하였다. 부들화분이 제거된 상등액 또는 여액을 동결건조하여 140mg 추출물을 수득하였다.10 ml of water was added to 1 g of the puddle and soaked in water for 4 hours at room temperature or 45 ° C. After 4 hours, the puddle remaining as precipitate was removed by centrifugation or filtration. The supernatant or filtrate from which the pollen was removed was lyophilized to obtain 140 mg extract.

실시예 2 : 부들화물 물 추출물의 침전Example 2: Precipitation of Butide Water Extract

부들화분 1g에 물 10ml를 가하고 상온 또는 45℃에서 4시간 동안 물에 침지하였다. 4시간 후 침전으로 남아있는 부들화분을 원심분리 또는 여과에 의해 분리하였다. 분리한 침전물에 다시 물 10ml을 가하여 상기와 동일한 방법에 의해 재추출하고 얻어진 추출액을 1차 추출액과 합하였다. 10 ml of water was added to 1 g of the puddle and soaked in water for 4 hours at room temperature or 45 ° C. After 4 hours, the puddle remaining as precipitate was separated by centrifugation or filtration. 10 ml of water was added to the separated precipitate, and the extract was reextracted by the same method as described above, and the obtained extract was combined with the primary extract.

상기 추출물의 혼합액에 100ml의 acetone을 가하고 1-2시간 방치하여 침전시킨 후 원심분리하고 침전물을 동결건조하여 ~20mg 추출물을 수득하였다.100 ml of acetone was added to the mixed solution of the extract and allowed to stand for 1-2 hours to precipitate, followed by centrifugation, and the precipitate was lyophilized to obtain ˜20 mg extract.

비교예Comparative example 1 : 청국장 물 추출물 1: Cheonggukjang water extract

부들화분 대신 청국장을 사용한 것을 제외하고는 실시예 1과 동일한 방법에 의해 180 mg의 추출물을 수득하였다.180 mg of the extract was obtained by the same method as Example 1, except that Cheonggukjang was used instead of the bud.

비교예 2 : 은행잎 물 추출물Comparative Example 2: Ginkgo Biloba Water Extract

부들화분 대신 파쇄한 은행잎을 사용한 것을 제외하고는 실시예 1과 동일한 방법에 의해 45 mg의 은행잎 추출물을 수득하였다.45 mg of ginkgo biloba extract was obtained by the same method as Example 1 except that the crushed ginkgo biloba leaves were used instead of the buds.

실시예 : 혈전용해능의 측정Example: Measurement of thrombolytic ability

fibrin plate법(Archs. Biochem. Biophysics. Vol. 40. PP 346(1952))에 의해 각 시료의 혈전용해능을 측정하여 비교하였다. 즉, 인산완충액에 fibrinogen을 녹여 이에 thrombin을 혼합하여 agarose가 함유된 배지를 petri dish에 분주하고 fibrin plate를 제조한 후 이에 시료 추출물을 paper disk에 점적하고 37℃에서 24시간 방치하여 얻어진 fibrin 용해환의 직경을 측정하여 혈전용해능의 정도로 하였다. The thrombolytic ability of each sample was measured and compared by fibrin plate method (Archs. Biochem. Biophysics. Vol. 40. PP 346 (1952)). That is, the fibrinogen was dissolved in phosphate buffer, thrombin was mixed, the agarose-containing medium was dispensed in a petri dish, a fibrin plate was prepared, and the sample extract was added to a paper disk and left for 24 hours at 37 ° C. The diameter was measured and made into the degree of thrombolytic ability.

도 1은 상기 실험에 의해 용해된 fibrin plate를 보여주는 사진이다. 도 1에서 부들 화분의 물 추출물을, 청국 A는 청국장 물 추출물을, 은행 A는 은행잎 물 추출물을 각각 사용한 결과이며, ( )안의 상온과 45℃는 추출시의 온도를 나타낸다.1 is a photograph showing a fibrin plate dissolved by the above experiment. In Fig. 1, the water extract of the bud pollen, Cheongguk A is the result of using the Cheonggukjang water extract, Ginkgo A is the ginkgo leaf water extract, respectively, the room temperature and 45 ℃ in () shows the temperature at the time of extraction.

도 1은 부들화분의 물 추출물의 혈전용해능을 청국장 및 은행잎의 물추출물과 비교하여 보여주는 사진.Figure 1 is a photograph showing the thrombolytic activity of the water extract of the bud pollen compared to the water extracts of Cheonggukjang and ginkgo biloba.

Claims (6)

부들화분 추출물을 유효성분으로 하는 항혈전용 조성물.Anti-thrombotic composition containing as an active ingredient the bud pollen extract. 부들화분에 5~20배(v/g)의 물을 가하여 추출하는 것을 특징으로 하는 항혈전용 조성물의 제조방법.Method for producing an anti-blood composition, characterized in that the extract by adding 5 to 20 times (v / g) of water to the bud. 제 2 항에 있어서,The method of claim 2, 상기 추출액을 동결건조하는 공정을 추가로 진행하는 것을 특징으로 하는 항혈전용 조성물의 제조방법.The method for producing an anti-blood composition, characterized in that for further proceeding the lyophilization of the extract. 제 2 항에 있어서,The method of claim 2, 상기 추출액에 (A) 추출액의 4~6배(v/v)의 아세톤을 투입하여 침전물을 형성하는 단계; 및 (B) 침전물을 여과한 후 동결건조하는 공정을 추가로 진행하는 것을 특징으로 하는 항혈전용 조성물의 제조방법.(A) adding 4-6 times (v / v) of acetone to the extract to form a precipitate; And (B) filtering the precipitate and then lyophilizing the preparation method. 제 2 항 내지 제 4 항 중 어느 한 항의 방법에 의해 제조된 항혈전용 조성물을 유효성분으로 하는 항혈전용 약제.An anti-thrombotic drug comprising the anti-thrombotic composition prepared by the method of any one of claims 2 to 4 as an active ingredient. 제 2 항 내지 제 4 항 중 어느 한 항의 방법에 의해 제조된 항혈전용 조성물을 유효성분으로 하는 항혈전 효과를 갖는 건강식품.A health food having an antithrombotic effect comprising the antithrombotic composition prepared by the method of any one of claims 2 to 4 as an active ingredient.
KR1020070106254A 2007-10-22 2007-10-22 Composition for anticoagulation comprising cattail pollen extracts KR100913370B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020070106254A KR100913370B1 (en) 2007-10-22 2007-10-22 Composition for anticoagulation comprising cattail pollen extracts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070106254A KR100913370B1 (en) 2007-10-22 2007-10-22 Composition for anticoagulation comprising cattail pollen extracts

Publications (2)

Publication Number Publication Date
KR20090040759A true KR20090040759A (en) 2009-04-27
KR100913370B1 KR100913370B1 (en) 2009-08-20

Family

ID=40764053

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020070106254A KR100913370B1 (en) 2007-10-22 2007-10-22 Composition for anticoagulation comprising cattail pollen extracts

Country Status (1)

Country Link
KR (1) KR100913370B1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101039145B1 (en) * 2010-09-07 2011-06-03 충남대학교산학협력단 A composition containing extract of typha angustata for preventing and treating circulatory diseases
KR20200069965A (en) * 2018-12-07 2020-06-17 안동대학교 산학협력단 Pharmaceutical composition comprising the extract of acorn pollen as an effective component for prevention or treatment of thrombosis and health functional food comprising the same
KR20210049641A (en) * 2019-10-27 2021-05-06 재단법인 경북바이오산업연구원 Pharmaceutical composition comprising the extraction of cattail pollen as an effective component for prevention or treatment of thrombosis and health functional food comprising the same
CN115413684A (en) * 2022-09-22 2022-12-02 烟台凯多海洋生物研究院有限公司 Homoptera insect repellent prepared from typha orientalis extract

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102291168B1 (en) 2018-10-31 2021-08-17 제주대학교 산학협력단 Compositions for the prevention or treatment of metabolic diseases containing extracts or fractions of Typha angustifolia
KR102158674B1 (en) 2018-12-07 2020-09-22 안동대학교 산학협력단 Pharmaceutical composition comprising the extract of darae pollen as an effective component for prevention or treatment of thrombosis and health functional food comprising the same
KR102216221B1 (en) 2019-02-08 2021-02-17 재단법인 경북바이오산업연구원 Pharmaceutical composition comprising the extract of pine pollen as an effective component for prevention or treatment of thrombosis and health functional food comprising the same

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101039145B1 (en) * 2010-09-07 2011-06-03 충남대학교산학협력단 A composition containing extract of typha angustata for preventing and treating circulatory diseases
KR20200069965A (en) * 2018-12-07 2020-06-17 안동대학교 산학협력단 Pharmaceutical composition comprising the extract of acorn pollen as an effective component for prevention or treatment of thrombosis and health functional food comprising the same
KR20210049641A (en) * 2019-10-27 2021-05-06 재단법인 경북바이오산업연구원 Pharmaceutical composition comprising the extraction of cattail pollen as an effective component for prevention or treatment of thrombosis and health functional food comprising the same
CN115413684A (en) * 2022-09-22 2022-12-02 烟台凯多海洋生物研究院有限公司 Homoptera insect repellent prepared from typha orientalis extract
CN115413684B (en) * 2022-09-22 2023-10-13 烟台固特丽生物科技股份有限公司 Homopteran insect repellent prepared from typha extract

Also Published As

Publication number Publication date
KR100913370B1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
KR100913370B1 (en) Composition for anticoagulation comprising cattail pollen extracts
US8618057B2 (en) Anticoagulant and composition for preventing thrombus containing poly-gamma-glutamic acid
CN106794210A (en) Comprising mangosteen extract or α, γ mangostin as the periodontosis prevention of active ingredient or improvement composition
ES2381851T3 (en) Procedure for obtaining an extract of blueberry pulp for use in the prevention and treatment of conditions such as caries, gingivitis and mild throat infections
WO2016015391A1 (en) Pharmaceutical composition for treating cardiovascular or cerebrovascular diseases and preparation method therefor
KR101117861B1 (en) A forsythoside injection and preparation thereof
JP2013511513A (en) Blood circulation improving composition containing dankobai extract as an active ingredient
CN101378790A (en) Compositions and methods for promoting the healing of tissue of multicellular organisms
KR101565856B1 (en) Composition for promoting osteogenic differentiation of human mesenchymal stem cells comprising cortex mori radicis extract, patrinia saniculaefolia extract or mixture thereof
JP4149545B2 (en) Low molecular weight fucans and pharmaceutical compositions thereof
KR20190087233A (en) The purple sweet potato composition manufactured by low temperature extraction method and the use thereof
JPS6130527A (en) Thrombolytic agent
EP2341925B1 (en) Thrombolytic/ anti thrombosis agent and its production method
KR20200062784A (en) Anti-Thrombotic Composition Comprising Fermented Garlic
CN106668131B (en) Earthworm composition and preparation method thereof
CN1548534B (en) Reptilase and its production process and application
JPH01180834A (en) Thrombolytic agent
CN1488399A (en) Medicinal use of agkistrodon acutus thrombase for treating hemorrhagic disease
KR20160120924A (en) Compositions for prevention or treatment of thrombosis comprising an extract of Opalopanax elatus
Ohkura Potential applications of Chinese herbal medicines with hemostatic properties
JPH0812586A (en) Antiplasmin agent
KR102296272B1 (en) A composition for improving memory and cognitive function, preventing and improving ischemia reperfusion injury including acorus gramineus soland extract
KR20170121061A (en) Anti-thrombotic composition comprising serine protease extracted from Diopatra Sugokai
KR102062136B1 (en) Phamaceutical composition for prevention or treatment of thrombosis comprising kyung-ok-go adding the silk of zea mays and pumpkin and health functional food comprising the same
KR101971256B1 (en) Antioxidant, anti-inflammatory and anti-histamine composition comprising a mixed herbal extract

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120730

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20130726

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20150807

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20160725

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20170728

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20180723

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20190730

Year of fee payment: 11